Tucson, AZ 的 非小細胞肺癌 臨床試驗
17 項針對 非小細胞肺癌 的研究正在 Tucson（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
招募中3 期
- The University of Arizona Cancer Center - North Campus ( Site 0163), Tucson
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #1, Tucson
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
招募中3 期
- The University of Arizona Cancer Center - North Campus, Tucson
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
招募中3 期
- Research Site, Tucson
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
招募中3 期
- Southern Arizona VA Health Care System, Tucson
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
招募中1/2 期
- Arizona Cancer Center at UMC North/University Medical Center, Tucson
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
招募中3 期
- Research Site, Tucson
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
招募中2/3 期
- Arizona Clinical Research Center, Tucson
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- The University of Arizona Cancer Center - North Campus, Tucson
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- USOR Arizona Oncology Associates, Tucson
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
招募中1/2 期
- University of Arizona Cancer Center, Tucson
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
招募中1 期
- University of Arizona, Tucson
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
招募中1 期
- University of Arizona Cancer Center - Tucson /ID# 262698, Tucson
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer
招募中歡迎健康志工
- University of Arizona Cancer Center, Tucson
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
招募中1/2 期
- Research Site 111, Tucson
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
招募中1 期
- The University of Arizona Cancer Center, Tucson
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
Tucson 的其他研究
- 乳癌20 項研究
- 肥胖症18 項研究
- 過重15 項研究
- 轉移性癌症14 項研究
- 癌症（所有類型）12 項研究
- 心血管疾病12 項研究
- 大腸直腸癌11 項研究
- 前列腺癌11 項研究
- 第二型糖尿病11 項研究
- 脂肪性肝病10 項研究
- 心臟衰竭10 項研究
- 高血壓10 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。